Relcovaptan (SR-49059) is a non-peptide vasopressin receptor antagonist, selective for the V1a subtype.[1] It has shown positive initial results for the treatment of Raynaud's disease and dysmenorrhoea, and as a tocolytic,[2] although it is not yet approved for clinical use.
References
- ^ Lemmens-Gruber R, Kamyar M (August 2006). "Vasopressin antagonists". Cellular and Molecular Life Sciences. 63 (15): 1766–79. doi:10.1007/s00018-006-6054-2. PMID 16794787. S2CID 30709102.
- ^ Decaux G, Soupart A, Vassart G (May 2008). "Non-peptide arginine-vasopressin antagonists: the vaptans". Lancet. 371 (9624): 1624–32. doi:10.1016/S0140-6736(08)60695-9. PMID 18468546. S2CID 1245079.